Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
HALO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading HALO News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
1.73%84.861.8%$758.98m
BIIBBiogen Inc.
1.34%245.061.0%$589.09m
CELGCelgene Corporation
2.10%100.701.2%$477.65m
AMGNAmgen Inc.
1.40%154.281.0%$456.38m
REGNRegeneron Pharmaceuticals, Inc.
2.65%358.503.1%$334.14m
ALXNAlexion Pharmaceuticals, Inc.
1.57%118.592.5%$316.39m
ILMNIllumina, Inc.
0.25%140.734.9%$170.13m
TSROTESARO, Inc.
-3.56%81.0615.8%$138.64m
VRTXVertex Pharmaceuticals Incorporated
2.00%87.742.6%$136.56m
BMRNBioMarin Pharmaceutical Inc.
4.60%81.384.0%$134.91m
MDVNMedivation, Inc.
-0.30%60.122.8%$132.56m
SRPTSarepta Therapeutics, Inc.
6.19%20.2549.4%$110.63m
AAgilent Technologies, Inc.
0.56%44.611.0%$104.97m
EXASExact Sciences Corporation
0.49%12.3121.4%$102.72m
ACADACADIA Pharmaceuticals Inc.
5.51%34.2519.6%$100.96m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel oncology therapies that target the tumor microenvironment. Its investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. Halozyme Therapeutics was founded by Gregory Ian Frost in 1998 and is headquartered in San Diego, CA.